sellWeak cluster of 2
David O. Watson sold $223k of APLS
General Counsel at Apellis Pharmaceuticals, Inc.. 3,905 shares at an average of $57.23, traded Dec 19, 2023, filed Dec 20, 2023.
Warning score
20Value
$223k
3,905 shares
Holdings after
89,753
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +12Trade size$223k at market
- 0Share of holdings soldSold 4.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001127602-23-030172, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | MOption exercise Common Stock | +7,905 | $13.85 | $109k | 93,658 | Dec 20, 2023 |
| Dec 19, 2023 | SOpen-market sale Common Stock | -1,605 | $57.00 | $91k | 92,053 | Dec 20, 2023 |
| Dec 19, 2023 | SOpen-market sale Common Stock | -2,300 | $57.38 | $132k | 89,753 | Dec 20, 2023 |
| Dec 19, 2023 | MOption exercise Stock Option (Right to Buy)derivative | -7,905 | $0.00 | $0 | 3,762 | Dec 20, 2023 |
Related signals
Other insiders at Apellis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | APLSsell Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $8,153 368 shares | -0% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $170k 7,832 shares | -8% | |
| 49Moderate | Apellis Pharmaceuticals, Inc. | Timothy Eugene Sullivan Chief Financial Officer | $224k 10,287 shares | -10% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Nur Nicholson Chief Technical Officer | $168k 7,725 shares | -10% | |
| 59Moderate | Apellis Pharmaceuticals, Inc. | Cedric Francois Chief Executive Officer | $592k 27,192 shares | -9% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Pascal Deschatelets Chief Scientific Officer | $129k 5,928 shares | -1% | |
| 38Weak | Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $73k 3,371 shares | -4% | |
| 36Weak | Apellis Pharmaceuticals, Inc. | James George Chopas VP/Chief Accounting Officer | $45k 2,064 shares | -4% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | Caroline Baumal Chief Medical Officer | $61k 2,797 shares | -3% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $49k 2,475 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.